Preclinical Models of Low-Grade Gliomas

被引:8
|
作者
Dasgupta, Pushan [1 ]
Balasubramanyian, Veerakumar [2 ]
de Groot, John F. F. [3 ]
Majd, Nazanin K. K. [2 ]
机构
[1] Univ Texas Austin, Dell Med Sch, Dept Neurol, Austin, TX 78712 USA
[2] UT MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA
[3] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA
关键词
glioma; low-grade glioma; preclinical models; IDH-mutant glioma; patient avatars; TERT PROMOTER MUTATIONS; SUBVENTRICULAR ZONE; IDH2; MUTATIONS; CANCER; TUMORS; ATRX; DIFFERENTIATION; SYSTEM; CLASSIFICATION; RADIOTHERAPY;
D O I
10.3390/cancers15030596
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Preclinical models are essential for the advancement of our understanding of glioma biology and the development of novel therapeutics. Much of our progress in the treatment of low-grade glioma has been hampered by our limited ability to develop ideal preclinical models. This has proven to be a formidable task given the complex factors one must account for, such as genetic background, intratumoral heterogeneity, intact blood-brain barrier, and the tumor microenvironment. As new knowledge is acquired regarding low-grade glioma, preclinical models must be refined and adjusted to reflect the actual biology of human glioma as closely as possible. In this review, we delve into in vitro and in vivo models of low-grade glioma with particular attention to illuminating the multifaceted task of developing the most optimal models. Diffuse infiltrating low-grade glioma (LGG) is classified as WHO grade 2 astrocytoma with isocitrate dehydrogenase (IDH) mutation and oligodendroglioma with IDH1 mutation and 1p/19q codeletion. Despite their better prognosis compared with glioblastoma, LGGs invariably recur, leading to disability and premature death. There is an unmet need to discover new therapeutics for LGG, which necessitates preclinical models that closely resemble the human disease. Basic scientific efforts in the field of neuro-oncology are mostly focused on high-grade glioma, due to the ease of maintaining rapidly growing cell cultures and highly reproducible murine tumors. Development of preclinical models of LGG, on the other hand, has been difficult due to the slow-growing nature of these tumors as well as challenges involved in recapitulating the widespread genomic and epigenomic effects of IDH mutation. The most recent WHO classification of CNS tumors emphasizes the importance of the role of IDH mutation in the classification of gliomas, yet there are relatively few IDH-mutant preclinical models available. Here, we review the in vitro and in vivo preclinical models of LGG and discuss the mechanistic challenges involved in generating such models and potential strategies to overcome these hurdles.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Prognostic Model and Nomogram Construction and Validation With an Autophagy-Related Gene Signature in Low-Grade Gliomas
    Li, Xinrui
    Huang, Zhiyuan
    Zhu, Lei
    Yu, Fei
    Feng, Minghao
    Gu, Aiqin
    Jiang, Jianxin
    Wang, Guangxue
    Huang, Dongya
    FRONTIERS IN GENETICS, 2022, 13
  • [22] Variations in the management of diffuse low-grade gliomas-A Scandinavian multicenter study
    Munkvold, Bodil Karoline Ravn
    Solheim, Ole
    Bartek, Jiri, Jr.
    Corell, Alba
    de Dios, Eddie
    Gulati, Sasha
    Helseth, Eirik
    Holmgren, Klas
    Jensdottir, Margret
    Lundborg, Mina
    Mireles, Eduardo Erasmo Mendoza
    Mahesparan, Ruby
    Tveiten, Oystein Vesterli
    Milos, Peter
    Redebrandt, Henrietta Nittby
    Pedersen, Lars Kjelsberg
    Ramm-Pettersen, Jon
    Sjoberg, Rickard L.
    Sjogren, Bjorn
    Sjavik, Kristin
    Smits, Anja
    Tomasevic, Gregor
    Vecchio, Tomas Gomez
    Vik-Mo, Einar O.
    Zetterling, Maria
    Salvesen, Oyvind
    Jakola, Asgeir S.
    NEURO-ONCOLOGY PRACTICE, 2021, 8 (06) : 706 - 717
  • [23] Preclinical modeling of lower-grade gliomas
    Tang, Lilly W.
    Mallela, Arka N.
    Deng, Hansen
    Richardson, Timothy E.
    Hervey-Jumper, Shawn L.
    McBrayer, Samuel K.
    Abdullah, Kalil G.
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [24] Low-grade gliomas in adults
    Sanai, Nader
    Chang, Susan
    Berger, Mitchel S.
    JOURNAL OF NEUROSURGERY, 2011, 115 (05) : 948 - 965
  • [25] Low-grade gliomas in adults
    Grier, Jeanine T.
    Batchelor, Tracy
    ONCOLOGIST, 2006, 11 (06) : 681 - 693
  • [26] Multicentric Low-Grade Gliomas
    Sridharan, Vishwajith
    Urbanski, Laura M.
    Bi, Wenya Linda
    Thistle, Katrina
    Miller, Michael B.
    Ramkissoon, Shakti
    Reardon, David A.
    Dunn, Ian F.
    WORLD NEUROSURGERY, 2015, 84 (04) : 1045 - 1050
  • [27] Pediatric Low-Grade Gliomas
    Sievert, Angela J.
    Fisher, Michael J.
    JOURNAL OF CHILD NEUROLOGY, 2009, 24 (11) : 1397 - 1408
  • [28] Chemotherapy for low-grade gliomas
    Reddy, AT
    Packer, RJ
    CHILDS NERVOUS SYSTEM, 1999, 15 (10) : 506 - 513
  • [29] EVIDENCE-BASED TREATMENT FOR LOW-GRADE GLIOMA
    Semmel, Deborah
    Ware, Courtney
    Kim, Jung Young
    Peters, Katherine B.
    SEMINARS IN ONCOLOGY NURSING, 2018, 34 (05) : 465 - 471
  • [30] Pediatric Low-Grade Gliomas
    Collins, Kelly L.
    Pollack, Ian F.
    CANCERS, 2020, 12 (05)